Compare MATW & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATW | STTK |
|---|---|---|
| Founded | 1850 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 639.2M | 652.4M |
| IPO Year | 1995 | 2020 |
| Metric | MATW | STTK |
|---|---|---|
| Price | $19.37 | $5.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $31.33 | $15.40 |
| AVG Volume (30 Days) | 670.0K | ★ 1.1M |
| Earning Date | 11-19-2026 | 11-13-2026 |
| Dividend Yield | ★ 5.27% | N/A |
| EPS Growth | ★ 59.07 | 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,795,737,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.42 | $1.72 |
| 52 Week High | $30.93 | $8.33 |
| Indicator | MATW | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 40.68 |
| Support Level | $18.58 | $5.19 |
| Resistance Level | $19.72 | $7.66 |
| Average True Range (ATR) | 0.44 | 0.35 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 74.75 | 24.23 |
Matthews International Corp is a provider of memorialization products, industrial technologies and brand solutions. The company's segments are Memorialization, Industrial Technologies and Brand Solutions. The memorialization offerings include bronze and granite memorials, caskets, and cremation-related products and equipment for cemeteries and funeral homes. Its Industrial Technologies segment designs, manufactures, services, and sells custom energy storage systems and product identification and warehouse automation solutions. The Brand Solutions segment provides brand management, pre-media, printing plates and cylinders, imaging, digital asset management, merchandising displays, and marketing and design services. The majority of revenue is generated by Memorialization.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.